In a breakthrough, US researchers have found that an improved tuberculosis vaccine can offer strong protection against leprosy.
“This is the first study demonstrating that an improved vaccine against tuberculosis also offers cross-protection against Mycobacterium leprae, the causative agent of leprosy,” said Marcus A. Horwitz, a professor of medicine and microbiology, immunology and molecular genetics from University of California Los Angeles.
That means that this vaccine has promise for better protecting against both major diseases at the same time.
- Twitter War Between Congress Leader Amarinder Singh & Delhi CM Arvind Kejriwal
- Life Of Actor-Dancer Ashwini Ekbote Who Died During A Performance
- Idea Exchange With Gurmeet Ram Rahim Singh
- PM Narendra Modi Bats For Equal Rights : Here What He Said On Triple Talaq
- Uncle Shivpal Targets Akhilesh, Claims CM Told Him He Will Form Another Party
- Pakistan Continues To Violate Ceasefire In RS Pura
- Samajwadi Party’s internal fight divides SP
- Cyrus Mistry Removed As Chairman of Tata Sons: Here’s What Happened
- Wreath Laying Ceremony Of Slain Soldier Sushil Kumar Observed
- Virat Kohli Powers India Home With Unbeaten 154
- Pakistan Resorts To Heavy Mortar Shelling, 1 BSF Jawan Dead, 3 Injured
- Bigg Boss 10 Weekend Ka Vaar: Priyanka Jagga Evicted
- Here’s How Much Army Welfare Fund Has After MNS Demanded Rs 5 Cr To Cast Pak Artistes
- Shiv Sena Chief Uddhav Thackeray Take A Jibe At MNS: Here’s What He Said
- Samajwadi Party Crisis Deepens: Here’s How It Will Impact UP Polls
“It also demonstrates that boosting a recombinant BCG vaccine further improves cross-protection against leprosy,” Horwitz added.
In many parts of the world, leprosy and tuberculosis live side-by-side.
Worldwide, there are approximately 233,000 new cases of leprosy per year, with nearly all of them occurring where tuberculosis is endemic.
The currently available century-old vaccine Bacille Calmette-Guerin (BCG) provides only partial protection against both tuberculosis and leprosy.
In lab experiments over mice, researchers found that rBCG30, a recombinant variant of BCG that overexpresses a highly abundant 30 kDa protein of the tuberculosis bacterium known as Antigen 85B, is superior to BCG in protecting against tuberculosis in animal models, and also cross protects against leprosy.
In addition, they found that boosting rBCG30 with the antigen 85B protein – a protein also expressed by the leprosy bacillus – provides considerably stronger protection against leprosy.
The next step is to test the rBCG30 vaccine for efficacy in humans against TB.
“If it is effective against TB, then the next step would be to test its effectiveness in humans against leprosy,” Horwitz noted in a paper published in the journal Infection and Immunity.